# US 2022/0031779 A1 · Oncolytic herpes simplex virus and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031779 A1
- Document ID: US20220031779A1
- Status: Published application
- Kind: A1
- Application number: 17/502,700
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2011-09-08
- Assignees: New York University; BeneVir Biopharm, Inc.
- Applicants: New York University; BeneVir Biopharm, Inc.
- Inventors: Ian J. Mohr; Matthew Mulvey
- Web page: https://patentgrep.com/patent/US20220031779A1

## CPC

- A61K 35/763: Herpes virus
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.

## Claims

### Claim 1

A variant herpes simplex virus (HSV) having an intact endogenous Us12 encoding gene and an intact endogenous Us11 encoding gene, lacking functional ICP34.5 encoding genes,
wherein each ICP34.5 encoding gene is replaced by a polynucleotide cassette comprising:
(a) a Us11 encoding gene operably associated with an immediate early (IE) promoter; and
(b) at least one heterologous gene encoding a polypeptide capable of enhancing an anti-tumor response.

### Claim 2 (depends on 1)

The variant HSV according to claim 1, in which said at least one heterologous gene encodes an immunomodulatory polypeptide.

### Claim 3 (depends on 2)

The variant HSV according to claim 2, in which the immunomodulatory polypeptide is selected from the group consisting of a TAP 1/2 (“TAP”) inhibitor, granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha and CD40 ligand (CD40L).

### Claim 4 (depends on 3)

The variant HSV according to claim 3, in which said at least one immunomodulatory polypeptide is GM-CSF.

### Claim 5 (depends on 1)

The variant HSV according to claim 1, in which said at least one heterologous gene encodes a prodrug converting enzyme.

### Claim 6 (depends on 1)

The variant HSV according to claim 1, comprising at least two (2) heterologous genes encoding a polypeptide capable of enhancing an anti-tumor response.

### Claim 7 (depends on 6)

The variant HSV according to claim 6, wherein said one of said two heterologous genes encodes a TAP inhibitor and the other encodes a mammalian GM-CSF.

### Claim 8 (depends on 7)

The variant HSV according to claim 7, in which the TAP inhibitor inhibits a non-human TAP.

### Claim 9 (depends on 8)

The variant HSV according to claim 8, in which the TAP inhibitor inhibits a murine TAP.

### Claim 10 (depends on 9)

The variant HSV according to claim 9, in which the TAP inhibitor is the UL49.5 polypeptide from bovine herpesvirus.

### Claim 11 (depends on 6)

The variant HSV according to claim 6, wherein one of said two heterologous genes encodes a TAP inhibitor and the other encodes a prodrug converting enzyme.

### Claim 12

A variant herpes simplex virus (HSV) having an intact endogenous Us12 encoding gene and an intact endogenous Us11 encoding gene, lacking functional ICP34.5 encoding genes,
wherein each ICP34.5 encoding gene is replaced by a polynucleotide cassette comprising:
(a) a Us11 encoding gene operably associated with an immediate early (IE) promoter; and
(b) a gene encoding an inhibitor of antigen presentation on class I major histocompatibility complex (MHC) molecules, wherein said inhibitor is capable of inhibiting antigen presentation on the surface of virally infected tumor cells.

### Claim 13 (depends on 12)

The variant HSV according to claim 12, wherein said inhibitor of antigen presentation is a TAP inhibitor.

### Claim 14 (depends on 12)

The variant HSV according to claim 12, in which the polynucleotide cassette additionally comprises a heterologous gene encoding a polypeptide capable of enhancing an anti-tumor response.

### Claim 15 (depends on 14)

The variant HSV according to claim 14, in which the heterologous gene encodes GM-CSF.

### Claim 16 (depends on 1)

The variant HSV according to claim 1, in which the IE promoter is an α27 IE promoter.

### Claim 17 (depends on 1)

The variant HSV according to claim 1, in which the heterologous gene is operably associated with a promoter selected from the group consisting of a CMV promoter and an EF1α promoter.

### Claim 18 (depends on 13)

The variant HSV according to claim 13, wherein said TAP inhibitor is a bovine herpesvirus (BHV) UL49.5 polypeptide.

### Claim 19

A variant herpes simplex virus (HSV) having an intact endogenous Us12 encoding gene and an intact endogenous Us11 encoding gene, lacking functional ICP34.5 encoding genes, wherein each ICP34.5 encoding gene is replaced with a polynucleotide cassette comprising a nucleic acid sequence set forth in one of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 25.

### Claim 20

A variant herpes simplex virus (HSV) having a genome sequence set forth in SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, or SEQ ID NO: 30.

### Claim 21 (depends on 1)

A pharmaceutical formulation comprising: the variant HSV according to claim 1, and a pharmaceutically acceptable carrier for administration to tumor cells.

### Claim 22 (depends on 21)

The pharmaceutical formulation according to claim 21, wherein said administration to tumor cells is in situ.

### Claim 23 (depends on 21)

The pharmaceutical formulation according to claim 21, wherein said virus selectively infects human bladder cancer cells, human melanoma cells, human ovarian cancer cells, or human glioblastoma cells.

### Claim 24 (depends on 21)

A method for killing tumor cells in a subject comprising: administering to a subject in need thereof the pharmaceutical formulation according to claim 21 under conditions effective to kill tumor cells in the subject.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the tumor cells are selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, medulloblastoma, melanoma cells, pancreatic cancer cells, prostate carcinoma cells, breast cancer cells, lung cancer cells, colon cancer cells, hepatoma cells, mesothelioma, bladder cancer cells, and epidermoid carcinoma cells.

### Claim 26 (depends on 24)

The method according to claim 24, wherein said virus selectively replicates in human bladder cancer cells, melanoma cells, ovarian cancer cells, or glioblastoma cells.

### Claim 27 (depends on 24)

The method according to claim 24, wherein the subject is a mammal.

### Claim 28 (depends on 24)

The method according to claim 24, wherein the mammal is a human.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the administration is carried out by injection, infusion, instillation or inhalation.

### Claim 30 (depends on 24)

A method for treating cancer, wherein said method comprises administering to an individual in need of treatment, a therapeutically effective amount of the pharmaceutical formulation according to claim 24.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the individual is a mammal.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the mammal is a human.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the cancer is selected from the group consisting of bladder cancer, melanoma, ovarian cancer and glioblastoma.
